SSY Group gains first-in-China NMPA registration for Safinamide Mesylate bulk drug

Bulletin Express05-26

SSY Group Limited announced that its Safinamide Mesylate has received registration approval from China’s National Medical Products Administration (NMPA), officially qualifying the compound as a bulk drug for market-ready preparations.

The approval gives SSY Group the distinction of being the first domestic enterprise to obtain such certification for Safinamide Mesylate in the People’s Republic of China. The product is indicated for use in combination with levodopa and other Parkinson’s disease therapies.

The update was disclosed through a voluntary filing dated 26 May 2026, signed by Executive Director and Company Secretary Chow Hing Yeung. The company stated the announcement serves to inform shareholders and potential investors of its latest product development milestone.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100770665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100770665","market":"us","top_or_hot":-1,"title":"SSY Group gains first-in-China NMPA registration for Safinamide Mesylate bulk drug","media":"Bulletin Express","content":"<p>SSY Group Limited announced that its Safinamide Mesylate has received registration approval from China’s National Medical Products Administration (NMPA), officially qualifying the compound as a bulk drug for market-ready preparations.</p>\n<p>The approval gives SSY Group the distinction of being the first domestic enterprise to obtain such certification for Safinamide Mesylate in the People’s Republic of China. The product is indicated for use in combination with levodopa and other Parkinson’s disease therapies.</p>\n<p>The update was disclosed through a voluntary filing dated 26 May 2026, signed by Executive Director and Company Secretary Chow Hing Yeung. The company stated the announcement serves to inform shareholders and potential investors of its latest product development milestone.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group gains first-in-China NMPA registration for Safinamide Mesylate bulk drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group gains first-in-China NMPA registration for Safinamide Mesylate bulk drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-26 08:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY Group Limited announced that its Safinamide Mesylate has received registration approval from China’s National Medical Products Administration (NMPA), officially qualifying the compound as a bulk drug for market-ready preparations.</p>\n<p>The approval gives SSY Group the distinction of being the first domestic enterprise to obtain such certification for Safinamide Mesylate in the People’s Republic of China. The product is indicated for use in combination with levodopa and other Parkinson’s disease therapies.</p>\n<p>The update was disclosed through a voluntary filing dated 26 May 2026, signed by Executive Director and Company Secretary Chow Hing Yeung. The company stated the announcement serves to inform shareholders and potential investors of its latest product development milestone.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1100770665","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100770665","pubTimestamp":1779755212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SSY Group Limited announced that its Safinamide Mesylate has received registration approval from China’s National Medical Products Administration (NMPA), officially qualifying the compound as a bulk...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团"},"translate_title":"SSY集团甲磺酸沙非酰胺原料药获得中国首个NMPA注册","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY Group Limited announced that its Safinamide Mesylate has received registration approval from China’s National Medical Products Administration (NMPA), officially qualifying the compound as a bulk drug for market-ready preparations.\nThe approval gives SSY Group the distinction of being the first domestic enterprise to obtain such certification for Safinamide Mesylate in the People’s Republic of China. The product is indicated for use in combination with levodopa and other Parkinson’s disease therapies.\nThe update was disclosed through a voluntary filing dated 26 May 2026, signed by Executive Director and Company Secretary Chow Hing Yeung. The company stated the announcement serves to inform shareholders and potential investors of its latest product development milestone.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100770665","isCrawlerRequest":true}